When Healthcare Costs Crack a Stock, LEAPS Traders Win
When a stock drops hard on cost concerns, the instinct is to short it, fade it, or ignore it entirely. That's the wrong reflex. Alignment Healthcare (ALHC) is getting punished right now because rising medical cost ratios are spooking institutional holders — including funds like Voya's MI Dynamic Small Cap Fund, which flagged the name in their Q3 2026 letter. But here's the contrarian read most traders are missing: aggressive repricing events in small-cap healthcare are historically where the most asymmetric LEAPS setups appear. The stock gets hit, implied volatility spikes, and the market starts pricing in a worst-case scenario that rarely fully materializes. If you know where to look, the rubble of a healthcare selloff can be a goldmine for patient options traders willing to think 12–18 months out.
What's Actually Happening
Alignment Healthcare (ALHC) operates as a tech-enabled, value-based care company focused on Medicare Advantage — a market that has been under serious structural pressure in 2025 and 2026. The core problem isn't unique to ALHC: across the Medicare Advantage space, medical cost ratios (MCRs) have been rising faster than premium revenue, squeezing margins across every operator in the sector. What set ALHC apart — and what made it a Voya holding worth calling out — was its growth profile and its exposure to a patient population that skews older and sicker than industry average.
The Voya MI Dynamic Small Cap Fund's Q3 2026 letter is worth reading not because of what it says about ALHC specifically, but because of what it reveals about institutional sentiment broadly. When small-cap fund managers start flagging cost concerns in their quarterly letters, it usually means the selling pressure has institutional legs — not just retail panic. That matters for options traders because institutional exit flows tend to be sustained and orderly, not impulsive. That means the downside may already be priced in, but the stock won't snap back overnight either. What you get is a window.
Meanwhile, Q3 saw the S&P 500 gain 2.30% and the Nasdaq add 2.47%, led by large-cap tech and energy. Small-cap healthcare was left behind entirely — which is exactly the kind of divergence that creates mispricing in the options market.
Why Options Traders Should Pay Attention
The options market tends to do something predictable when a small-cap stock gets punished on fundamental concerns: it overprices near-term downside protection and underprices long-dated recovery optionality. Right now, with ALHC under pressure, short-dated puts are expensive and near-term implied volatility (IV) is elevated. That's not where you want to play.
What you should be watching is what happens to deep out-of-the-money (OTM) calls on the longer-dated contracts — the 12 to 24-month LEAPS. When IV is elevated across the board, traders instinctively gravitate toward the near-term options because that's where the action is. But LEAPS on small-cap names like ALHC can sit quietly underpriced, especially when the market narrative is universally bearish. Nobody is buying recovery calls when the institutional letters are out citing cost concerns.
That narrative vacuum is the opportunity. Here's the specific dynamic to understand: if ALHC's underlying cost issues stabilize — which they historically do as Medicare Advantage plans recalibrate premiums and renegotiate with providers — the stock could see a meaningful re-rating. A move from, say, deeply depressed levels back toward previous trading ranges would be unremarkable from a business standpoint but explosive for a deep OTM call purchased at $0.03–$0.06. You're not betting on a miracle; you're betting on mean reversion in a sector that has reliably mean-reverted over multi-year cycles.
The catalyst timing matters too. Medicare Advantage rate announcements, quarterly earnings with updated medical cost ratio guidance, and broader CMS policy signals are all concrete events that can reprice ALHC sharply. LEAPS give you the runway to be right on direction without being forced to be right on timing.
The LEAPS Angle
Let's get specific about the structure. Deep OTM LEAPS calls — those priced in the $0.01 to $0.08 range on large-cap or liquid small-cap names — are designed for exactly this kind of setup. You're allocating a small, defined dollar amount for maximum asymmetry. If ALHC (ALHC) is trading at, say, $8–$10 and you're buying calls struck at $15 or $18 expiring in January 2028, you're paying pennies for a scenario where the stock recovers meaningfully and those calls go from worthless to worth multiples of your entry.
The math is straightforward. A $0.05 call that moves to $0.80 on a recovery is a 16x return. You don't need ALHC to become a market darling — you just need it to stop being priced for bankruptcy. That's a much lower bar.
The key variables to screen for are: low absolute premium ($0.01–$0.08), sufficient open interest to ensure you can exit the position, a strike price that represents a realistic but not trivial recovery scenario, and an expiration far enough out to give the fundamental story time to develop. This is precisely the type of setup that tools like the StrikeEdge scanner are built to surface — it combs through the options chain looking for deep OTM LEAPS on liquid names where premium is in that penny range before a potential catalyst or re-rating event. Instead of manually scanning hundreds of chains, traders use it to shortlist names like ALHC where the asymmetry is mathematically interesting.
For ALHC specifically, the thesis doesn't require a turnaround in the entire Medicare Advantage market. It requires:
- Medical cost ratio stabilization — even a modest improvement in guidance removes the worst-case narrative
- Revenue growth continuation — ALHC has had a compelling top-line story; that doesn't disappear because margins are squeezed
- Sector re-rating — if large-cap peers like UnitedHealth (UNH) or Humana (HUM) signal stabilization, ALHC gets pulled higher with the tide
- Acquisition premium — value-based care assets with scale have been acquisition targets; that optionality is real and not priced into distressed LEAPS
None of these are guaranteed outcomes. All of them are plausible over an 18-month window. That's the LEAPS thesis in one sentence.
Key Risks to Watch
The risks here are real and deserve honest treatment. First, Medicare Advantage cost pressure could be structural rather than cyclical — if CMS continues to tighten reimbursement rates while medical inflation persists, ALHC's margin recovery could take longer than a 2-year LEAPS window allows. The position expires worthless if the story doesn't develop in time.
Second, small-cap healthcare names have liquidity risk in their options chains. Wide bid-ask spreads can destroy your entry and exit economics on positions this small. Always check open interest and volume before entering — a LEAPS with 50 contracts of open interest is not a position you can exit cleanly if sentiment shifts.
Third, institutional continued selling — as evidenced by funds like Voya flagging concerns — can keep a lid on price recovery even when fundamentals begin to improve. Sentiment takes time to turn.
Finally, any broader healthcare regulatory risk (new CMS rules, Medicaid restructuring, or Medicare Advantage market exits by major players) could reset the entire sector's valuation framework in ways that make individual LEAPS positions irrelevant.
Size accordingly. These are lottery-ticket sized positions, not core holdings.
The Alignment Healthcare (ALHC) selloff is a reminder that institutional pain creates retail opportunity — but only if you're looking at the right timeframe and the right instrument. Deep OTM LEAPS in this price range let you express a recovery thesis with minimal capital at risk and maximum upside if the story plays out. Screen your chains carefully, check liquidity, and let the trade structure do the risk management for you. The market rarely hands you asymmetry this cleanly packaged.
Share this article
Related Articles
Fed December Hike? The 90-Day Trade Most Traders Miss
Everyone is debating whether the Fed hikes in December. The smarter question is what happens 60–90 days after the decision — and which deep OTM LEAPS are already pricing in the wrong answer. History gives you an edge here, if you know where to look.
Tech Just Had Its Worst Day in 6 Years. Here's the Trade.
The S&P 500 tech sector just posted its largest single-day drop in over six years — and panic-driven IV compression in surviving large-caps is quietly creating some of the cheapest deep OTM LEAPS setups of 2024. Here's how to read the wreckage.
Fed December Shock: The LEAPS Setup Traders Are Missing
Everyone is debating whether the Fed hikes in December. The smarter question is what happens to large-cap options pricing in the 6–18 months after the decision lands. History has an uncomfortable answer for anyone sitting in cash.